Precision Biologics to give presentation at CICON 2023, Milan, Italy – shares new NEO-201 data from current Phase 2 Clinical Trial
Precision Biologics announces that Massimo Fantini PhD, our Director of Research and Development, will deliver...
Precision Biologics announces that Massimo Fantini PhD, our Director of Research and Development, will deliver...
A poster will be presented in person at the American Association for Cancer Research (AACR)...
Precision Biologics, Inc. publishes data and analysis from recent First-In-Human Phase 1 Clinical Trial With...
Dr. Philip M. Arlen, President and CEO, Precision Biologics, gives keynote address entitled “Preclinical/Clinical Development...
Society for the Immunotherapy of Cancer 2022 Annual Meeting, November 8 – 12, Boston, MA,...
Dr. Philip M. Arlen gives presentation “Preclinical/Clinical Development of a Neo-Epitope Targeted Monoclonal Antibody for...
Precision Biologics, Inc. and our collaborators at the NCI deliver a poster presentation at the...
Dr. Philip M. Arlen gives Immunotherapy Section Opening Keynote at Festival of Biologics 2022, San...
Dr. Philip M. Arlen gives scientific presentation at Biomarkers UK: In-Person, Day 1 – November...
The Phase 2 Clinical Trial with a safety lead in, combining Precision Biologics monoclonal antibody...